Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jenkins’ Exit Interview: He’ll Miss Insider Status Upon FDA Departure

Executive Summary

Outgoing US FDA Office of New Drugs director tells the Pink Sheet being on the outside will take some adjustment.


Related Content

US FDA's Biosimilars Chief Leah Christl Plans Departure
Trump’s Rx For The Drug Industry: Take Two And Have No Idea What Will Happen In The Morning
Possible Trump FDA Commish Candidate Favors (Much) Lighter Touch
Jenkins' Retirement From US FDA Was Several Years In The Making
'Brilliant' and 'Steady' Jenkins Retiring From US FDA's Office of New Drugs
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Oral History Of Drug Development: FDA’s Califf Wants Woodcock, Temple To Share Their Stories
Plan B Decision May Offer FDA Best Political Protection Available
Plan B Decision Mobilizes House Members To Seek FDA Integrity Review


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts